Roundtable Discussion: Charting the Future of Microbiome-Driven Cancer Therapy: Integration, Innovation & Translation
Time: 12:00 pm
day: Conference Day One, Track Two, AM
Details:
- Reflect on key learnings from MaaT013 and KAN-001 to evaluate what defines a clinically successful and scalable microbiome-based oncology therapy
- Discuss the current barriers to integrating microbiome interventions with standard-of-care cancer therapies, particularly in immune-oncology and GI cancers
- Identify priority areas for biomarker development, patient stratification, and regulatory clarity to accelerate clinical translation
- Explore what’s needed to move from trial success to routine clinical practice—considering manufacturing, commercialization, and payer engagement
